AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27168463 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen (FP) patch
Number of subjects: 633
Study 24977699 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise
Number of subjects: 15
Study 24977699 — intervention group
Group type: COMPARATOR
Intervention: Land-based exercise
Number of subjects: 15
Study 23233136 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine + metoclopramide (10 mg)
Number of subjects: 90
Study 23233136 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine + ketamine (5 mg)
Number of subjects: 90
Study 23233136 — intervention group
Group type: COMPARATOR
Intervention: lidocaine (20 mg)
Number of subjects: 90
Study 21518592 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg/d)
Number of subjects: 172
Study 21518592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 19006748 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharp-edged intraocular lenses (IOLs)
Number of subjects: 26
Study 19006748 — intervention group
Group type: COMPARATOR
Intervention: Round-edged intraocular lenses (IOLs)
Number of subjects: 26
Study 16835999 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (LFD) (20-25% of energy content)
Number of subjects: 44
Study 16835999 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HFD) (40-45% of energy content)
Number of subjects: 44
Study 12949426 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Number of subjects: 0
Study 12949426 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 11121907 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily
Number of subjects: 96
Study 11121907 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg twice daily
Number of subjects: 96
Study 9100593 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human IGF-I (rhIGF-I) therapy (80 micrograms.kg.day)
Number of subjects: 43
Study 9100593 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy alone
Number of subjects: 43
Study 8112546 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal endoscopy without sedation
Number of subjects: 65
Study 8112546 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal endoscopy with sedation using i.v. midazolam at a dosage of 0.05 mg/kg
Number of subjects: 65
Study 3595668 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (20 mg/week)
Number of subjects: 128
Study 3595668 — intervention group
Group type: COMPARATOR
Intervention: VAC (vincristine, Adriamycin and cyclophosphamide)
Number of subjects: 128
Study 29671383 — intervention group
Group type: EXPERIMENTAL
Intervention: Basketball intervention group (6-week programme)
Number of subjects: 87
Study 29671383 — intervention group
Group type: COMPARATOR
Intervention: Basketball control group
Number of subjects: 87
Study 29671383 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer intervention group
Number of subjects: 87
Study 27225729 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy yogurt supplemented with rhamnogalacturonan (RG) - 150 mL daily containing 50 mg of probiotics and 100 mg of hallabong peel polysaccharide (60% RG) for 8 weeks
Number of subjects: 120
Study 27225729 — intervention group
Group type: COMPARATOR
Intervention: Placebo group - same product without hallabong peel supplement for 8 weeks
Number of subjects: 120
Study 27225729 — intervention group
Group type: COMPARATOR
Intervention: Both groups (test and placebo)
Number of subjects: 120
Study 24184850 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Position and Control movement strategy (Core‐PAC) warm‐up
Number of subjects: 20
Study 24184850 — intervention group
Group type: COMPARATOR
Intervention: Standard warm-up
Number of subjects: 20
Study 21748368 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% CHO-E solution
Number of subjects: 7
Study 21748368 — intervention group
Group type: COMPARATOR
Intervention: 2% CHO-E solution
Number of subjects: 7
Study 21748368 — intervention group
Group type: COMPARATOR
Intervention: 10% CHO-E solution
Number of subjects: 7
Study 21748368 — intervention group
Group type: EXPERIMENTAL
Intervention: All carbohydrate concentrations
Number of subjects: 7
Study 20300897 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 2
Study 20300897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 18823182 — intervention group
Group type: EXPERIMENTAL
Intervention: Volitional help sheet
Number of subjects: 193
Study 18823182 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (Questionnaire‐only; questionnaire plus planning instruction; questionnaire, planning instruction plus volitional help sheet without explicit instruction)
Number of subjects: 193
Study 16060184 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease-modulating matrix (Promogran)
Number of subjects: 80
Study 16060184 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressings
Number of subjects: 80
Study 12422579 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg + clarithromycin 500 mg + amoxycillin 1000 mg (RBCCA)
Number of subjects: 256
Study 12422579 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg + clarithromycin 500 mg + metronidazole 500 mg (RBCCM)
Number of subjects: 256
Study 12422579 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg + clarithromycin 500 mg + amoxycillin 1000 mg (OCA)
Number of subjects: 256
Study 12422579 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg + clarithromycin 500 mg + metronidazole 500 mg (OCM)
Number of subjects: 256
Study 10325898 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 5'-monophosphate (AMP)
Number of subjects: 18
Study 10325898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10325898 — intervention group
Group type: COMPARATOR
Intervention: Guanosine 5'-monophosphate (GMP)
Number of subjects: 18
Study 10325898 — intervention group
Group type: COMPARATOR
Intervention: Non-allergic controls after AMP
Number of subjects: 18
Study 9122012 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive treatment in group I (61 patients with glomerular disease at diagnosis)
Number of subjects: 99
Study 9122012 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive treatment in group II (24 patients with restrained disease activity)
Number of subjects: 99
Study 9122012 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive treatment in group III (14 patients with active glomerulopathy)
Number of subjects: 99
Study 9122012 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC and UIC detection
Number of subjects: 99
Study 9122012 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological findings related to UC3
Number of subjects: 99
Study 9122012 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological findings related to CIC
Number of subjects: 99
Study 9122012 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary excretion of IC
Number of subjects: 99
Study 9122012 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous excretion of C4 in urine
Number of subjects: 99
Study 1745621 — intervention group
Group type: EXPERIMENTAL
Intervention: 500-mg ETA suppository
Number of subjects: 12
Study 1745621 — intervention group
Group type: COMPARATOR
Intervention: 250-mg ETA tablets
Number of subjects: 12
Study 1745621 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppository
Number of subjects: 12
Study 1745621 — intervention group
Group type: COMPARATOR
Intervention: Two placebo tablets
Number of subjects: 12
Study 7035987 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (320 mg given in 8 doses over a period of 24 hours)
Number of subjects: 9
Study 7035987 — intervention group
Group type: COMPARATOR
Intervention: Frusemide (40 mg)
Number of subjects: 9
Study 30684965 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin plus placebo (CC)
Number of subjects: 64
Study 30684965 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain omega-3 polyunsaturated fatty acids plus placebo (FO)
Number of subjects: 64
Study 30684965 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin plus long-chain omega-3 polyunsaturated fatty acids (CC-FO)
Number of subjects: 64
Study 30684965 — intervention group
Group type: COMPARATOR
Intervention: Double placebo (PL)
Number of subjects: 64
Study 28320856 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreflex activation therapy
Number of subjects: 383
Study 25403347 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical yoga
Number of subjects: 159
Study 25403347 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy
Number of subjects: 159
Study 25403347 — intervention group
Group type: COMPARATOR
Intervention: Self-care advice
Number of subjects: 159
Study 24014831 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 145 (420 mg subcutaneously every 4 weeks for ≥12 weeks, then every 2 weeks for an additional 12 weeks)
Number of subjects: 8
Study 21636687 — intervention group
Group type: EXPERIMENTAL
Intervention: Written Emotional Disclosure (WED)
Number of subjects: 31
Study 21636687 — intervention group
Group type: COMPARATOR
Intervention: Time management narratives
Number of subjects: 31
Study 19684298 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendon autograft
Number of subjects: 64
Study 19684298 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendon autograft
Number of subjects: 64
Study 17228169 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with standardized, aluminum hydroxide‐adsorbed J. ashei extract (100 IR, 54 microg of Jun a 1/ml)
Number of subjects: 40
Study 17228169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14706600 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical skills laboratory course on CVC (n = 12)
Number of subjects: 26
Study 14706600 — intervention group
Group type: COMPARATOR
Intervention: Traditional group (n = 14)
Number of subjects: 26
Study 11330757 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training using arm-propelled three-wheeled chair (APTWC) for 12 weeks
Number of subjects: 12
Study 11330757 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 12
Study 9578793 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballard method (external criteria only)
Number of subjects: 0
Study 9578793 — intervention group
Group type: COMPARATOR
Intervention: Dubowitz method
Number of subjects: 0
Study 8484655 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser treatment
Number of subjects: 85
Study 8484655 — intervention group
Group type: COMPARATOR
Intervention: Dye laser treatment
Number of subjects: 85
Study 3434348 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol treatment continued after negative cultures
Number of subjects: 24
Study 3434348 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol treatment withdrawn after negative cultures
Number of subjects: 24
Study 31255494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively Normal (CN) participants with higher plasma Aβ1‐42 levels
Number of subjects: 2840
Study 31255494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively Normal (CN) participants
Number of subjects: 2840
Study 31255494 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild Cognitive Impairment (MCI) participants
Number of subjects: 2840
Study 29095133 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help CBT (GSH-CBT)
Number of subjects: 396
Study 29095133 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face CBT
Number of subjects: 396
Study 29095133 — intervention group
Group type: COMPARATOR
Intervention: Continued Guided self-help CBT (GSH)
Number of subjects: 396
Study 29095133 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care model (GSH followed by face-to-face CBT for non-responders)
Number of subjects: 396
Study 27792719 — intervention group
Group type: EXPERIMENTAL
Intervention: Maggot debridement therapy (MDT)
Number of subjects: 19
Study 27792719 — intervention group
Group type: COMPARATOR
Intervention: Surgical debridement and topical application of silver sulfadiazine (SSD)
Number of subjects: 19
Study 25523578 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) treatment for 1 week
Number of subjects: 50
Study 25523578 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) treatment for 2 weeks
Number of subjects: 50
Study 25523578 — intervention group
Group type: COMPARATOR
Intervention: OVA-challenged 1 week
Number of subjects: 50
Study 25523578 — intervention group
Group type: COMPARATOR
Intervention: OVA-challenged 2 weeks
Number of subjects: 50
Study 25523578 — intervention group
Group type: COMPARATOR
Intervention: Normal control
Number of subjects: 50
Study 22646167 — intervention group
Group type: EXPERIMENTAL
Intervention: CAO + S (simvastatin 20 mg)
Number of subjects: 113
Study 22646167 — intervention group
Group type: COMPARATOR
Intervention: CAO + P (placebo)
Number of subjects: 113
Study 20621700 — intervention group
Group type: COMPARATOR
Intervention: Standard duration therapy (24 weeks)
Number of subjects: 268
Study 20621700 — intervention group
Group type: COMPARATOR
Intervention: Variable duration therapy (VD12 for 12 weeks and VD24 for 24 weeks)
Number of subjects: 268
Study 20621700 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable duration therapy (VD12 for 12 weeks)
Number of subjects: 268
Study 20621700 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable duration therapy (VD24 for 24 weeks)
Number of subjects: 268
Study 17826201 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TSE treatment
Number of subjects: 58
Study 17826201 — intervention group
Group type: COMPARATOR
Intervention: Sham TSE treatment
Number of subjects: 58
Study 17826201 — intervention group
Group type: EXPERIMENTAL
Intervention: Active and Sham TSE treatments
Number of subjects: 58
Study 15780157 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer (PSA test)
Number of subjects: 0
Study 15780157 — intervention group
Group type: COMPARATOR
Intervention: Control (no screening)
Number of subjects: 0
Study 12886046 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional membrane and LDL apheresis (group C)
Number of subjects: 30
Study 12886046 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-coated membrane and LDL apheresis (group D)
Number of subjects: 30
Study 12886046 — intervention group
Group type: COMPARATOR
Intervention: Conventional cellulose or synthetic membranes (group A)
Number of subjects: 30
Study 12886046 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E-coated membrane (group B)
Number of subjects: 30
Study 10578484 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (350 mg)
Number of subjects: 21
Study 10578484 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol (250 mg)
Number of subjects: 21
Study 10578484 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (60 mg)
Number of subjects: 21
Study 10578484 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (80 micrograms as sodium selenite)
Number of subjects: 21
Study 10578484 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (350 mg) + RRR-alpha-tocopherol (250 mg)
Number of subjects: 21
Study 8722735 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive, multimodal analgesia
Number of subjects: 30
Study 8722735 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity at 24 hours after surgery (rest and after movement)
Number of subjects: 30
Study 8722735 — intervention group
Group type: EXPERIMENTAL
Intervention: McGill Pain Questionnaire data at 24 and 48 hours
Number of subjects: 30
Study 8722735 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled morphine consumption (mg)
Number of subjects: 30
Study 8722735 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain thresholds to pressure applied to a rib contralateral to the incision
Number of subjects: 30
Study 1914760 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg by mouth 2 hr before the start)
Number of subjects: 30
Study 1914760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6350957 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g of ornidazole
Number of subjects: 59
Study 6350957 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g of ornidazole
Number of subjects: 59
Study 6350957 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g of ornidazole
Number of subjects: 59
Study 30508633 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus Rhamnosus GG (LGG)
Number of subjects: 61
Study 30508633 — intervention group
Group type: COMPARATOR
Intervention: No probiotics (Control)
Number of subjects: 61
Study 28270284 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline flush at 3.0 ml/s (40 ml) - Group A
Number of subjects: 68
Study 28270284 — intervention group
Group type: COMPARATOR
Intervention: Saline flush at 4.0 ml/s (40 ml) - Group B
Number of subjects: 68
Study 28270284 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study 26846324 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (50 mg/day)
Number of subjects: 60
Study 26846324 — intervention group
Group type: COMPARATOR
Intervention: Placebo (standard neonatal nutrition)
Number of subjects: 60
Study 26846324 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 60
Study 26846324 — intervention group
Group type: COMPARATOR
Intervention: DHA supplementation and placebo
Number of subjects: 60
Study 23750967 — intervention group
Group type: EXPERIMENTAL
Intervention: Perspective change of 45°
Number of subjects: 0
Study 23750967 — intervention group
Group type: EXPERIMENTAL
Intervention: Perspective change > 45°
Number of subjects: 0
Study 23750967 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of rotation
Number of subjects: 0
Study 23750967 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric polyhedrons
Number of subjects: 0
Study 23750967 — intervention group
Group type: EXPERIMENTAL
Intervention: Slant
Number of subjects: 0
Study 22391417 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational baby books
Number of subjects: 167
Study 22391417 — intervention group
Group type: COMPARATOR
Intervention: Non-educational baby books
Number of subjects: 167
Study 22391417 — intervention group
Group type: COMPARATOR
Intervention: No books
Number of subjects: 167
Study 20660695 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 72
Study 20660695 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy controls from North America)
Number of subjects: 72
Study 20660695 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (in patients with SLCO1B1 genotype c.463CA)
Number of subjects: 72
Study 20660695 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (in patients with SLCO1B1 genotype c.463CC)
Number of subjects: 72
Study 17674476 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antiviral therapy (CAT)
Number of subjects: 32
Study 17674476 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment (control group)
Number of subjects: 32
Study 16639914 — intervention group
Group type: EXPERIMENTAL
Intervention: P-100 device
Number of subjects: 0
Study 16639914 — intervention group
Group type: COMPARATOR
Intervention: Meniett device
Number of subjects: 0
Study 12637183 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial casting for 5 weeks
Number of subjects: 10
Study 10595875 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-diameter suction system (5/8‐inch open‐bore suction tip and 3/4‐inch tubing attached to a 1‐inch pour spout)
Number of subjects: 0
Study 10595875 — intervention group
Group type: COMPARATOR
Intervention: Standard suction systems (small-diameter blunt‐nosed and medium-diameter open‐bore 1/4‐inch suction tips connected to 1/4‐inch tubing)
Number of subjects: 0
Study 8942410 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged garlic extract (7.2 g per day)
Number of subjects: 41
Study 8942410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 1916166 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-rectal pulsed irrigation
Number of subjects: 34
Study 1916166 — intervention group
Group type: COMPARATOR
Intervention: Per-oral colonic lavage
Number of subjects: 34
Study 6345426 — intervention group
Group type: EXPERIMENTAL
Intervention: Conalbumin plus traditional dietetic therapy
Number of subjects: 40
Study 6345426 — intervention group
Group type: COMPARATOR
Intervention: Traditional dietetic therapy
Number of subjects: 40
Study 29607730 — intervention group
Group type: EXPERIMENTAL
Intervention: Rank-Preserving Structural Failure Time Model (RPSFTM) applied to simulated datasets with varying levels of crossover.
Number of subjects: 0
Study 29607730 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazard Ratio (HR) analysis using RPSFTM.
Number of subjects: 0
Study 25730587 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV DNA self-sampling
Number of subjects: 0
Study 25730587 — intervention group
Group type: EXPERIMENTAL
Intervention: Pap smear
Number of subjects: 0
Study 25730587 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV DNA self-sampling and Pap smear
Number of subjects: 0
Study 24716847 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel 300 mcg/day
Number of subjects: 92
Study 24716847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 23442823 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-CV booster dose
Number of subjects: 450
Study 23442823 — intervention group
Group type: COMPARATOR
Intervention: JE-CV
Number of subjects: 450
Study 19945815 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated medical interview (video)
Number of subjects: 100
Study 19945815 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-only version of the interview
Number of subjects: 100
Study 19945815 — intervention group
Group type: COMPARATOR
Intervention: Transcribed version of the interview
Number of subjects: 100
Study 18194330 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental hygienist brushing teeth and applying Duraphat vanish to active root caries lesions once a month
Number of subjects: 215
Study 18194330 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 ppm F-toothpaste used twice a day
Number of subjects: 215